CN101433654B - 一种治疗妇女慢性盆腔炎的中药制剂及其制备方法 - Google Patents
一种治疗妇女慢性盆腔炎的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN101433654B CN101433654B CN200810238466XA CN200810238466A CN101433654B CN 101433654 B CN101433654 B CN 101433654B CN 200810238466X A CN200810238466X A CN 200810238466XA CN 200810238466 A CN200810238466 A CN 200810238466A CN 101433654 B CN101433654 B CN 101433654B
- Authority
- CN
- China
- Prior art keywords
- parts
- portions
- medicine
- preparation
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 117
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 230000001684 chronic effect Effects 0.000 title claims abstract description 39
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 title claims description 43
- 241001649190 Campsis Species 0.000 claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 28
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims abstract description 9
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 9
- 229940097275 indigo Drugs 0.000 claims abstract description 9
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 56
- 241000628997 Flos Species 0.000 claims description 44
- 239000002994 raw material Substances 0.000 claims description 22
- 239000000865 liniment Substances 0.000 claims description 21
- 229940040145 liniment Drugs 0.000 claims description 21
- 210000000582 semen Anatomy 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000829 suppository Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 238000012856 packing Methods 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 235000005903 Dioscorea Nutrition 0.000 claims description 8
- 241000234273 Dioscorea Species 0.000 claims description 8
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 8
- 241001126925 Lobata Species 0.000 claims description 8
- 241000245240 Lonicera Species 0.000 claims description 8
- 241000545442 Radix Species 0.000 claims description 8
- 241000501098 Sargentodoxa Species 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229920000742 Cotton Polymers 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 95
- 239000008280 blood Substances 0.000 abstract description 94
- 230000017531 blood circulation Effects 0.000 abstract description 19
- 239000009636 Huang Qi Substances 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 240000008488 Thlaspi arvense Species 0.000 abstract 2
- 235000008214 Thlaspi arvense Nutrition 0.000 abstract 2
- 235000017303 Althaea rosea Nutrition 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000218033 Hibiscus Species 0.000 abstract 1
- 235000017881 Hibiscus moscheutos subsp moscheutos Nutrition 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000132171 Phryma leptostachya Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 230000007778 menstrual function Effects 0.000 abstract 1
- 235000007180 rose mallow Nutrition 0.000 abstract 1
- 239000009910 sargent gloryvine Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 39
- 208000002193 Pain Diseases 0.000 description 31
- 201000010099 disease Diseases 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 230000001737 promoting effect Effects 0.000 description 29
- 231100000614 poison Toxicity 0.000 description 24
- 210000003734 kidney Anatomy 0.000 description 17
- 239000003440 toxic substance Substances 0.000 description 17
- 235000009508 confectionery Nutrition 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 208000033809 Suppuration Diseases 0.000 description 13
- 210000001015 abdomen Anatomy 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 11
- 210000004291 uterus Anatomy 0.000 description 11
- 206010007247 Carbuncle Diseases 0.000 description 10
- 208000019255 Menstrual disease Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 208000006820 Arthralgia Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000005906 menstruation Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 206010013935 Dysmenorrhoea Diseases 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 208000005171 Dysmenorrhea Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000025747 Rheumatic disease Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000000552 rheumatic effect Effects 0.000 description 7
- 206010000087 Abdominal pain upper Diseases 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 6
- 206010001928 Amenorrhoea Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 231100000540 amenorrhea Toxicity 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 241000762515 Hydrosalpinx Species 0.000 description 5
- 208000007893 Salpingitis Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 208000030843 hydrosalpinx Diseases 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000001047 pyretic effect Effects 0.000 description 5
- 206010040872 skin infection Diseases 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010003011 Appendicitis Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003860 topical agent Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010037714 Quadriplegia Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000002605 anti-dotal effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000003119 painkilling effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000014786 phosphorus Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010051244 Dyschezia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 206010034240 Pelvic congestion Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940071110 amino-cerv Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical group CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗妇女慢性盆腔炎的中药制剂及其制备方法。内服药物为:丹参10~20份,黄芪10~20份,红藤10~20份,当归10~20份,桃仁10~20份,败酱草10~20份,鸡血藤10~20份,赤芍10~20份,凌霄花5~15份,山药10~20份,枸杞5~10份,大枣10~20份;外敷药物为:金黄散10~30份,透骨草10~30份,金银花10~30份,鸡血藤10~30份,地肤子10~30份,青黛10~30份,蛇床子10~30份,败酱草10~30份,地桃花10~20份,蒲公英10~20份,凌霄花10~30份。本发明活血化淤,调经养血,制作方法简单,能取得良好经济效益。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物原料的医用配制品,特别涉及一种治疗妇女慢性盆腔炎的中药制剂及其制备方法。
背景技术
慢性盆腔炎是妇科常见病、难治病,有缠绵不愈、易于复发的特点,是国内外妇科治疗中的一大难题慢性盆腔炎多为急性盆腔炎治疗不彻底,患者遇感冒、劳累过度等导致抗病力低下,病源菌又活跃起来致盆腔炎症复发,亦有部分患者并无急性炎症史,因起病缓慢,忽视治疗所致。其病理改变为盆腔内炎性渗出、器官粘连、局部组织瘢痕增生,子宫固定不动。盆腔瘀血则月经量多,卵巢功能损害则月经失调,输卵管粘连则不孕,输卵管积水则卵巢囊肿。祖国医学认为该病多由经行产后胞脉空虚,外感湿邪热毒内侵胞宫;或脾肾虚损,水湿内停日久化热;或过食肥甘厚味,内生湿热,下注胞宫;或肝郁气滞化火,痰火流注胞宫,致盆腔脏器内膜气血运行不畅,湿邪热毒、痰火瘀血互结,化腐成脓,损害盆腔组织。由于失治或误治,致反复发作,迁延不愈,器官组织粘连、增生而成瘕包块。该病虚实夹杂、湿热痰瘀相互为患,脾肾虚损是其本,湿热痰瘀阻滞是其标。我国及世界范围内,妇女慢性盆腔炎的发病率均呈上升趋势,严重损害了广大妇女的身心健康,给生活带来不尽的麻烦,而治疗这一顽疾一直没有有效的方法。慢性盆腔炎的病人大都反复发作,缠绵难愈,影响生活质量。多数病人虽多方求治,但一般都效果不佳,导致焦虑、抑郁,进而更进一步加重病情,严重影响工作及生活质量。
发明内容
本发明所要解决的技术问题在于,提供了一种治疗慢性盆腔炎的中药制剂,针对妇科疾病中盆腔炎的药物的疗效均不理想,见效较慢,且易反复的缺点,在传统医学的基础上结合多年临床经验,采用现代加工方法精心研制而成。本发明对原料药品的各有效成分科学配伍,是一种见效快、副作用小、抑菌性强的药物,能有效解除患者的痛苦。
为解决上述技术问题,本发明提供了一种治疗妇女慢性盆腔炎的中药制剂,由内服和外敷药物组成,所述内服药物中各种原料的重量份数比为:丹参10~20份,黄芪10~20份,红藤10~20份,当归10~20份,桃仁10~20份,败酱草10~20份,鸡血藤10~20份,赤芍10~20份,凌霄花5~15份,山药10~20份,枸杞5~10份,大枣10~20份;
所述外敷药物中,各种原料的重量份数比为:金黄散10~30份,透骨草10~30份,金银花10~30份,鸡血藤10~30份,地肤子10~30份,青黛10~30份,蛇床子10~30份,败酱草10~30份,地桃花10~20份,蒲公英10~20份,凌霄花10~30份。
所述治疗妇女慢性盆腔炎的中药制剂,内服药物中各种原料的重量份数比优选为:丹参10~15份,黄芪10~15份,红藤10~20份,当归10~20份,桃仁10~20份,败酱草10~20份,鸡血藤10~20份,赤芍10~15份,凌霄花5~10份,山药10~15份,枸杞5~10份,大枣10~15份;
所述外敷药物中,各种原料的重量份数比优选为:金黄散10~20份,透骨草10~15份,金银花10~30份,鸡血藤10~20份,地肤子10~20份,青黛10~15份,蛇床子10~20份,败酱草10~30份,地桃花10~20份,蒲公英10~20份,凌霄花10~30份。
所述治疗妇女慢性盆腔炎的中药制剂,内服药物中各种原料的重量份数比还可优选为:丹参10~20份,黄芪10~15份,红藤10~20份,当归10~20份,桃仁10~20份,败酱草10~15份,鸡血藤10~15份,赤芍10~15份,凌霄花5~15份,山药10~15份,枸杞5~10份,大枣10~15份;
所述外敷药物中,各种原料的重量份数比还可优选为:金黄散20~30份,透骨草10~20份,金银花10~30份,鸡血藤10~20份,地肤子10~20份,青黛10~15份,蛇床子10~20份,败酱草20~30份,地桃花10~20份,蒲公英10~20份,凌霄花20~30份。
所述治疗妇女慢性盆腔炎的中药制剂,内服药物中各种原料的重量份数比也可优选为:丹参10~20份,黄芪10~15份,红藤10~20份,当归10~15份,桃仁15~20份,败酱草10~15份,鸡血藤15~20份,赤芍10~15份,凌霄花5~15份,山药10~20份,枸杞5~10份,大枣10~15份;
所述外敷药物中,各种原料的重量份数比为:金黄散15~30份,透骨草10~20份,金银花10~20份,鸡血藤10~30份,地肤子10~20份,青黛10~15份,蛇床子10~20份,败酱草20~30份,地桃花10~20份,蒲公英10~20份,凌霄花15~20份。
所述内服药物,在使用时煎汤剂服用,可以每日1剂,水煎分两次服,每7天为一疗程。
所述内服药物剂型可以为片剂或散剂,服用时,可以一天三次,每7天为一疗程。
所述内服药物的剂型可以为:蜜炼丸剂、水合丸剂、胶囊、口服液、颗粒剂、胶剂或糖浆剂。
为解决上述技术问题,本发明又提供了一种治疗妇女慢性盆腔炎的中药制剂的制备方法,所述内服药物散剂的制备包括:
粉碎的步骤:将所述原料按配比混合,投入粉碎机粉碎成细粉,粒度为80~120目;
混合的步骤:将上述步骤所得细粉投入混合搅拌机充分混匀;
包装的步骤:将混匀后的细粉用小瓶或包装盒分装,每3~5克为一瓶或一盒分装。
为解决上述技术问题,本发明还提供了一种治疗妇女慢性盆腔炎的中药制剂的制备方法,所述外敷药物的制备包括以下步骤:
将所述原料加水浸泡30分钟至1小时,加热煮沸30~40分钟,过滤,滤液备用;滤渣加水第二次加热,煮沸30~40分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸40~50分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉状;以每袋0.5~2g分装袋中,即成粉剂中成药。
所述外敷药物剂型可以为栓剂,制备的步骤可以包括:
取半合成脂肪酸甘油酯、羊毛脂、聚乙二醇和泊洛沙姆poloxamer中一种或多种作为基质;
将所述基质在温度50℃~60℃条件下加热融化,加入所述外敷药物的粉剂中成药,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,插入棉栓,冷却定型制成子弹头状栓剂;所述粉剂中成药与基质的配比为1∶2~1∶4;所述棉栓为尾部带有棉线的棉栓。
本发明采用药栓和棉栓一体工艺,弥补了普通栓剂的不足,普通栓剂不能有效送达到阴道的深处。由于阴道的自净作用,当有异物存在时,会增加液体分泌,在短时间内将药物排除体外,既降低了疗效,又延长了疗程,增加费用又污染内衣裤。而本发明克服这一技术难题,制成的栓剂可充分发挥药物疗效,具有安全性好,可行性好的优点,能直达病灶,达到祛病目的。
与现有技术相比教,本技术具有给药方便,药剂易于制造,成本低廉等优点。本发明采用不同药性的中药材,进行了科学配伍,能达到理想的治疗效果,且安全,毒副作用小,使用方便,治愈时间短,治愈后不易复发。能创造较好的社会价值及经济利益。
具体实施方式
盆腔炎,相当于祖国医学中的“带下病”、“月经不调”、“痛经”、“症瘕”等疾病范畴中。该疾病的发病原因多为分娩、流产、妇科手术或月经后,血窦开放,有所不慎,湿热邪毒乘虚而入,若邪气盛正气亦盛,则病情来势较猛,若邪盛正虚,则急性炎症状况不甚明显。多因失治误治而转为慢性阶段。临床以慢性盆腔炎者最多见。其病机为湿浊、湿热、寒湿邪毒蕴结瘀滞在胞宫、胞脉,以致经络闭阻不通,气机不畅,气血凝滞而成。因而急性期要用大剂量的清热解毒,利湿活血化瘀之剂。慢性期是由急性期迁延而来,由于经络瘀滞日久,所以要以活血化瘀,清热、利湿为主,酌加益气之品,还要辨清湿浊的性质,灵活地加入健脾利湿或清热解毒、温阳化湿的药物,不可墨守常规。故宜健脾益肾祛痰湿、清热解毒疏肝、活血化瘀散结为基本治法。
本发明的目的,就是针对妇科疾病中盆腔炎的药物的疗效均不理想,见效较慢,对人体副作用大,对妇女身体危害较大,且易反复的缺点,发明生产一种见效快、副作用小、抑菌性强的药物,以解除患者的痛苦。本发明继承祖国的医学遗产,将中华医药发扬光大,利用满山遍野的中草药资源优势,研制一种特效、安全、方便、价廉、纯天然的中药制剂,用以治疗妇女的各种盆腔炎等常见妇科病,多发病,弥补西药毒副作用大,对妇女身体危害深等缺陷。本发明制备工艺简单,药物原料价格低廉,疗效好,能达到比较好的社会效果及经济利益。
本发明内服中药选用凌霄花,之甘凉,清热利湿,消炎解毒使之下焦胞宫郁热得清,水湿得利,热毒得除;《本草纲目》云:“败酱,善排脓破血,故仲景治痈,及古方妇人科皆用之,乃至易得之物,而后人不知用,盖未遇识者耳。”实验证明败酱草、红藤、能增强网状细胞和白细胞的吞噬能力,提高机体抗感染力,促进抗体形成及提高血清中溶菌酶水平,从而达到抗菌消炎的目的。而以鸡血藤、桃仁,丹参活血祛瘀,补血调经,从而共成清热利湿,祛瘀止痛,大枣,当归,黄芪,枸杞,山药补而不燥,利于温补之功效。赤芍能清血分实热,散瘀血留滞实乃治疗妇科内淤的良药。根据中医“久病多虚、久病多瘀”的理论,治疗以扶正祛邪为原则,实在所治疗妇女痛经带下、盆腔、阴道、附件等各种炎症之良方。
桃仁苦,甘,平为血瘀血闭之专药。苦以泄滞血,甘以生新血。《药品化义》:桃仁,味苦能泻血热,体润能滋肠燥。若连皮研碎多用,走肝经,主破蓄血,逐月水,及遍身疼痛,四肢木痹,左半身不遂,左足痛甚者,以其舒经活血行血,有去瘀生新之功,若去皮捣烂少用,入大肠,治血枯便闭,血燥便难,以其濡润凉血和血,有开结通滞之力。
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。.《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。
枸杞是一味常用的补肝益肾中药,现代医学研究证实其含有甜菜硷、多糖、粗脂肪、粗蛋白、胡萝卜素、维生素A、维生素C、维生素B1、维生素B2及钙、磷、铁、锌、锰、亚油酸等营养成分,对造血功能有促进作用,还能抗衰老、抗突变、抗肿瘤、抗脂肪肝及降血糖等作用。中医常常用它来治疗肝肾阴亏、腰膝酸软、头晕、健忘、目眩、目昏多泪、消渴、遗精等病症,滋阴养肾功效显著。
山药,含有多种营养素,有强健机体,滋肾益精的作用。大凡肾亏遗精,妇女白带多、小便频数等症,皆可服之。是补肾良药。
当归:其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药。大约佐之以补则补,故能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证。营虚而表不解者,佐以柴、葛、麻、桂等剂,大能散表卫热,而表不敛者,佐以大黄之类,又能固表。惟其气辛而动,故欲其静者当避之,性滑善行,大便不固者当避之。凡阴中火盛者,当归能动血,亦非所宜,阴中阳虚者,当归能养血,乃不可少。
大枣:富含蛋白质、脂肪、糖类、胡萝卜素、B族维生素、维生素C、维生素P以及钙、磷、铁和环磷酸腺苷等营养成分中医中药理论认为,红枣具有补虚益气、养血安神、健脾和胃等作用,是脾胃虚弱、气血不足、倦怠无力、失眠多梦等患者良好的保健营养品果。大枣补中益气,养血安神。用于脾虚食少,乏力便溏,妇人脏躁。能行气,活血,调经。用于月经不调,红崩,白带,是补血佳品。
黄芪以补虚为主,能补气固表,利尿托毒,排脓,敛疮生肌。用于气血不足、疮疡内陷、脓成不溃或久溃不敛者。黄芪具有很好的托毒生肌的功能,即久不愈合的脓肿化脓生肌。现代医学研究表明,黄芪内含而多种抗菌有效成分,而且能增强机体的免疫功能,因此还能用于预防某些传染病的发生。《本草逢原》载:“黄芪能补五脏诸虚,治脉弦自汗,泻阴火,去肺热,无汗则发,有汗则止。”是增进抵抗力和防御疾病的良药。
红藤味苦性平,入大肠经。功用清热解毒、活血散瘀、祛风杀虫。用于肠痈腹痛、风湿痹痛、跌打伤痛,妇女痛经,赤痢,血淋,疳积虫痛等症。
赤芍味苦,微寒。归肝经。功能主治清热凉血,散瘀止痛。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。赤芍能清血分实热,散瘀血留滞。本品功能与丹皮相近,故常与丹皮相须为用。但丹皮清热凉血的作用较佳,既能清血分实热,又能治阴虚发热;而赤芍只能用于血分实热,以活血散瘀见长。
鸡血藤性苦、甘,温。归肝、肾经,补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛活血舒筋;养血调经,《本草纲目拾遗》载其能医手足麻木;肢体瘫痪;风湿痹痛;妇女有经不调;痛经。
凌霄花一种传统中药材,具有行血去瘀、凉血祛风利湿,清热解毒,味辛酸,性微寒归肝、心包经、功能活血散瘀,凉血祛风。主治月经不调、经闭症瘕、产后乳肿、皮肤瘙痒.《本草衍义补遗》:凌霄花,治血中痛之要药也,且补阴捷甚,盖有守而独行,妇人方中多用何哉。《南宁市药物志》:有消炎解毒、止血止痛、排脓生肌之功,治红白痢。
败酱草性味苦平,具有清热解毒、排脓破瘀的功效。能医肠痈、下痢、赤白带下、产后瘀滞腹痛、目赤肿痛。入胃、大肠、肝经。主治清热解毒,消痈排脓,活血行瘀。用于肠痈、肺痈及疮痈肿毒,实热瘀滞所致的胸腹疼痛,产后瘀滞腹痛等症。
外敷药物中金黄散有较强的清热解毒,消肿止痛作用,可以改善局部血运及淋巴回流,疏通微循环,增强免疫,改善血管通透性,促进炎症水肿吸收、消散。其治疗痈、疽、疖、疔等急性化脓性疾病,疗效确切,故《外科正宗》曰:“凡外科一切诸般顽恶肿毒,随手用之,无不应效,诚为疮家良便方也。”慢性盆腔炎,病程缠绵,加之抗生素的滥用,耐药菌株耐药性增加,西医治疗往往难以奏效“,久病成瘀”,慢性盆腔炎者无论哪一型,多有瘀滞存在,外敷金黄散,能使药证结合,现代药理实验研究证明:金黄散对各种细菌均有不同程度的控制作用,其中溶血性链球菌最为敏感。金黄散还可以提高白细胞的趋向性及吞噬作用,使白细胞向感染病灶围聚对致病菌进行吞噬。故金黄散外敷治疗慢性盆腔炎,可使炎症迅速得到控制,缩短治疗时间,明显改善症状。
本发明中的金黄散是采用下述方法制成的:黄柏1两,蜂蜜2两,将蜜涂于黄柏,小火烤至蜂蜜渗入黄柏中,研磨为粉即成。
蛇床子性辛、苦,温;有小毒。归肾经。主治温肾壮阳,燥湿,祛风,杀虫。用于阳痿,宫冷,寒湿带下,湿痹腰痛;外治外阴湿疹,妇人阴痒;滴虫性阴道炎,是妇科外用良药。《本草经疏》载:蛇床子,味苦平;《别录》辛甘无毒;今详其气味,当必兼温燥,阳也。故主妇人阴中肿痛,男子阴痿湿痒,除痹气,利关节,恶疮。《别录》温中下气,令妇人子服热,男子阴强,令人有子。盖以舌能除湿,温能散寒,辛能润肾,甘能益脾,故能除妇人男子一切虚寒湿所生病。寒湿既除,则病去,性能益阳,故能已疾,而又有补益也。
地肤子性寒,味辛、苦。能清热利湿,祛风止痒。用于小便涩痛、阴痒带下、风疹、湿疹、皮肤瘙痒等症。《要药分剂》载:″入肾、膀胱二经。利小便,清湿热。治小便不利,淋病,带下,疝气,风疹,疮毒,疥癣,阴部湿痒。
透骨草性味甘,性辛,温。《本草原始》:“味甘,无毒。《中药志》:“辛,温。”入肺、肝经。主治祛风除湿,解毒止痛。用于风湿关节痛;外用治疮疡肿毒。
鸡血藤性苦、甘,温。归肝、肾经,补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛活血舒筋;养血调经,《本草纲目拾遗》载其能医手足麻木;肢体瘫痪;风湿痹痛;妇女有经不调;痛经。
凌霄花一种传统中药材,具有行血去瘀、凉血祛风利湿,清热解毒,味辛酸,性微寒归肝、心包经、功能活血散瘀,凉血祛风。主治月经不调、经闭症瘕、产后乳肿、皮肤瘙痒.《本草衍义补遗》:凌霄花,治血中痛之要药也,且补阴捷甚,盖有守而独行,妇人方中多用何哉。《南宁市药物志》:有消炎解毒、止血止痛、排脓生肌之功,治红白痢。也所一味外用妇科良药。
败酱草性味苦平,具有清热解毒、排脓破瘀的功效。能医肠痈、下痢、赤白带下、产后瘀滞腹痛、目赤肿痛。入胃、大肠、肝经。主治清热解毒,消痈排脓,活血行瘀。用于肠痈、肺痈及疮痈肿毒,实热瘀滞所致的胸腹疼痛,产后瘀滞腹痛等症。
青黛具有清热,凉血,解毒的功效,且性甘,平,无毒,入肝、肺、胃经。清热解毒,凉血,定惊,用于温毒发斑,血热吐衄,胸痛咳血,口疮,痄腮,据《要药分剂》载:除热解毒,兼能凉血。《雷公炮制药性解》载:“入肝,脾二经。”
蒲公英是一味常用的中药,其药用价值早已载入各种医书。它全草入药,含蒲公英甾醇、蒲公英赛醇、蒲公英苦素、咖啡酸、胆碱、菊糖等成分。性平味甘微苦。可清热解毒,消肿散结。《本草纲目》记载:“解食毒,散滞气,清热毒,化食毒,消恶肿、结核、疔肿。”。蒲公英昧甘平,其性无毒。当是入肝入胃,解热凉血之要药。
金银花清热散毒,《本草纲目》载“金银花,善于化毒,故治痈疽、肿毒、疮癣......”。自古以来,金银花常用于清热解毒,治疗温病发热,热毒血痢,痈疡等症。现代药理研究表明,金银花具有抑菌、抗病毒、抗炎、解热、调节免疫等作用中医认为,金银花性寒、味甘、气平,具有清热解毒之功效,可以治疗热毒肿疡、痈疽疔疮等症。且兼有宣散作用。金银花清热解毒作用颇强,在外科中为常用之品。
地桃花性甘,淡,平入心、肺经。功效祛风利湿,清热解毒。主治感冒发热,风湿痹痛,痢疾,水肿,白带,吐血,痈肿,外伤出血,毒蛇咬伤,急惊风,破伤风,哮喘,胃痛产后风。.《陆川本草》载:破积,散毒。治跌打损伤,疮痈,是治疗妇科的外科良药。
本中药制剂内外兼治,调经养血,标本兼治,内服外敷药物两者相互促进,提高妇女自身免疫力,并对人体不产生任何副作用,安全有效,能达到祛病强体的目的。
本发明治疗慢性盆腔炎中药组合物,内服药物散剂的制备包括以下步骤:将所述原料按配比混合,投入粉碎机粉碎成细粉,粒度为80~120目;将上述步骤所得细粉投入混合搅拌机充分混匀;将混匀后的细粉用小瓶或包装盒分装,每3~5克为一瓶或一盒分装。
本发明治疗慢性盆腔炎的中药组合,外敷药剂的制备方法为:选购配方中的药材,除杂质,将药材加水浸泡30分钟至1小时,加热煮沸35分钟,过滤,滤液备用。滤渣加水,第二次加热,煮沸35分钟,再过滤,滤液备用;滤渣再加水,第三次加热煮沸45分钟,过滤。将三次滤液合在一起,加热浓缩至糊状,放入烘箱,控制在80℃,烘干后冷却,研末成细粉状。以每袋1g分袋入塑料袋中,即成粉剂中成药。药剂用法:治疗慢性盆腔炎时,取本品2g加入温开水2000毫升坐浴,使药液浸泡病变位20至30分钟,每日一次。每7天一疗程。
本发明治疗慢性盆腔炎的中药组合,外敷药剂可以单独使用,作为妇科洗液,预防治疗各种慢性盆腔炎的妇科用药。
本发明治疗慢性盆腔炎中药组合物,外敷药剂制成栓剂,则取基质加热融化,温度50℃~60℃,加入本发明的药细粉,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,插入棉栓,冷却定型制成类似子弹头状栓剂。一般所用基质可为:半合成脂肪酸甘油酯、羊毛脂、聚乙二醇,药细粉与基质的配比为1∶2~1∶4,优选为1∶3,或采用泊洛沙姆poloxamer作为基质,其已被广泛用作栓剂的亲水性基质,具有以下优点:比其他基质的溶解度柔和、快速,载药量也较高。
所述栓剂的具体用法如下:将本发明药物栓剂除去塑料外壳,取出药栓,拉出尾部棉线,将药栓纳入阴道深部,棉线留在体外,每晚1粒,次日晨起拉出棉栓,连续用药7天为一疗程。
本发明的药效学研究及毒性(以栓剂为例)研究如下:
1.体外抗菌试验
对乙型链球菌、金黄色葡萄球菌、大肠杆菌的最小抑制浓度为1∶150,淋球菌为1∶150,白色念珠菌为1∶300,对阴道滴虫1∶20稀释度时的杀灭时间为5分钟,1∶50时为10分钟,1∶100时为20分钟,1∶200时为40分钟,1∶400时为8小时。
2.急性毒性试验:以本发明临床日用量的200倍给白鼠阴道内投药,观察7日。结果所有动物健存,其活动、饮食、毛发、排泄物未发现异常,未见毒性反应。
3.皮肤刺激性试验
取家兔剃毛,对该制剂进行诱导和激发接触试验,在24小时和48小时后观察试验家兔,均不见皮肤有红斑及水肿等现象,与阴性对照组无差异。结果表明,该制剂对皮肤反应强度近于零,即无皮肤变态反应。
对白鼠阴道和破损皮肤进行刺激性试验,未见有刺激性反应和其它不良。
毒性试验证明:该药未有毒性作用和不良反应,临床应用安全可靠。
实施例1陈某,42岁,患者绝育3年,带下痛经两年余。近1年来黄白带下严重,味腥臭,腰腹坠痛,月事错前(23左右),色黯质浓,7d方干净,经前感觉会阴及腹部胀痛,状如临盆,苦涩不堪,须用止痛片方能缓解。患者舌红、苔薄黄,脉细数弦。妇科检查:外阴已产式,阴道充血,宫颈下唇中糜,附件右侧增厚压痛,宫体大小正常,白带镜检:红血球(+),脓球(+++),证属湿浊之邪久滞带脉,瘀热互结成为带下,治宜燥湿,清热,利湿。使用如下配方:
内服药物为:丹参10g,黄芪10g,红藤10g,当归10g,桃仁10g,败酱草10g,鸡血藤10g,赤芍10g,凌霄花5g,山药10g,枸杞5g,大枣10g;
外敷药物为:金黄散20g,透骨草15g,金银花10g,鸡血藤20g,地肤子20g,青黛10g,蛇床子20g,败酱草30g,地桃花10g,蒲公英20g,凌霄花30g。
内服本发明中药制剂散剂4个疗程,外敷药物4个疗程见效。渐觉带下减少,色转浅淡,腰腹坠痛明显减轻,经期已可停服镇痛剂,再使用本中药制剂三个疗程渐愈。
实施例2王某,31岁,自述半年来,双侧小腹隐痛,坠痛不止,伴有腰酸痛,白带量多、色黄、月经基本规律,时心烦易怒,大便干结,外院曾诊:右侧输卵管积水4×3×2cm,左侧输卵管积水5×6×5cm。建议手术,未同意,抗生素治疗半月,病状未明显缓解。诊见:形体消瘦、舌质黯红、舌尖有瘀点,脉弦细。双合诊:子宫后位、常大,活动欠佳。举痛(+),B超提示:左侧输卵管积水7×5×3cm、右侧输卵管积水2×3×3cm。治宜活血散瘀,化痰通络。使用如下配方:
内服药物为:丹参20g,黄芪15g,红藤20g,当归20g,桃仁20g,败酱草15g,鸡血藤15g,赤芍15g,凌霄花15g,山药15g,枸杞10g,大枣15g;
外敷药物为:金黄散30g,透骨草20g,金银花30g,鸡血藤10g,地肤子10g,青黛15g,蛇床子10~20g,败酱草20~30g,地桃花20g,蒲公英10g份,凌霄花20g。
内服本发明中药制剂5疗程,外用中药制剂外敷5疗程见效,经查症状明显减轻,白带色清。复查B超:右侧附件未见异常,左侧输卵管增粗约2cm左右,继续治疗3疗程后,输卵管通水检查,通水过程顺利,于同年12月受孕,次年顺产一男婴。
实施例3金某,35岁,患者3年前患急性盆腔炎在医院住院治疗2周,症状改善后出院。遇情志不舒、劳累过度、或食辛燥食物即觉胸肋及下腹胀痛,嗳气,便秘,行经前后和性交后腰骶部酸胀痛不适,神疲乏力,带下色黄粘稠,反复发作。妇科检查:阴道内见黄色分泌物;宫颈光滑有举痛;子宫正常大小,轻度压痛;附件左侧团块增厚,有压痛,右侧增厚,压痛明显。实验室检查:阴道分泌物查霉菌、滴虫(-),白细胞计数(7);血常规正常。B超检查提示:“盆腔积液”。诊断为慢性盆腔炎。辨证属脾肾虚损,气滞血瘀,湿热互结胞宫。治宜健脾益肾,清热利湿,行气活血,化瘀散结。使用如下配方:
内服药物为:丹参15g,黄芪15g,红藤15g,当归10g,桃仁20g,败酱草15g,鸡血藤15g,赤芍10g,凌霄花5g,山药20g,枸杞5g,大枣10g;
外敷药物为:金黄散30g,透骨草20g,金银花20g,鸡血藤30g,地肤子20g,青黛15g,蛇床子20g,败酱草30g,地桃花10g,蒲公英20g,凌霄花20g。
内服本发明中药制剂3疗程,外用本中药制剂3疗程诸症消失,妇科及B超检查未见异常。随访一年未见复发。
在52例慢性盆腔炎患者中,年龄25-65岁,小于49岁者45例,未产妇6例,经产妇46例,药物治疗在月经干净第3~5天开始,治疗期间禁止性生活和阴道冲洗,避免全身和阴道使用其他抗生素。于停药后3~7天随访。用药四个疗程显效达92%。共治愈42例,显效8例,无效或效果不明显2例,治愈率达80.8%,总有效率达96.2%。本发明中药制剂一般3至4个疗程生效,用药5-6疗程后病症基本消失痊愈。停用后一般无复发。
Claims (10)
1.一种治疗妇女慢性盆腔炎的中药制剂,其特征在于,由内服药物和外敷药物组成,
所述内服药物中各种原料的重量份数比为:丹参10~20份,黄芪10~20份,红藤10~20份,当归10~20份,桃仁10~20份,败酱草10~20份,鸡血藤10~20份,赤芍10~20份,凌霄花5~15份,山药10~20份,枸杞5~10份,大枣10~20份;
所述外敷药物中,各种原料的重量份数比为:金黄散10~30份,透骨草10~30份,金银花10~30份,鸡血藤10~30份,地肤子10~30份,青黛10~30份,蛇床子10~30份,败酱草10~30份,地桃花10~20份,蒲公英10~20份,凌霄花10~30份;
所述金黄散是采用下述方法制成的:黄柏1两,蜂蜜2两,将蜂蜜涂于黄柏,小火烤至蜂蜜渗入黄柏中,研磨为粉即成。
2.根据权利要求1所述治疗妇女慢性盆腔炎的中药制剂,其特征在于,所述内服药物中各种原料的重量份数比为:丹参10~15份,黄芪10~15份,红藤10~20份,当归10~20份,桃仁10~20份,败酱草10~20份,鸡血藤10~20份,赤芍10~15份,凌霄花5~10份,山药10~15份,枸杞5~10份,大枣10~15份;
所述外敷药物中,各种原料的重量份数比为:金黄散10~20份,透骨草10~15份,金银花10~30份,鸡血藤10~20份,地肤子10~20份,青黛10~15份,蛇床子10~20份,败酱草10~30份,地桃花10~20份,蒲公英10~20份,凌霄花10~30份。
3.根据权利要求1所述治疗妇女慢性盆腔炎的中药制剂,其特征在于,所述内服药物中各种原料的重量份数比为:丹参10~20份,黄芪10~15份,红藤10~20份,当归10~20份,桃仁10~20份,败酱草10~15份,鸡血藤10~15份,赤芍10~15份,凌霄花5~15份,山药10~15份,枸杞5~10份,大枣10~15份;
所述外敷药物中,各种原料的重量份数比为:金黄散20~30份,透骨草10~20份,金银花10~30份,鸡血藤10~20份,地肤子10~20份,青黛10~15份,蛇床子10~20份,败酱草20~30份,地桃花10~20份,蒲公英10~20份,凌霄花20~30份。
4.根据权利要求1所述治疗妇女慢性盆腔炎的中药制剂,其特征在于,所述内服药物中各种原料的重量份数比为:丹参10~20份,黄芪10~15份,红藤10~20份,当归10~15份,桃仁15~20份,败酱草10~15份,鸡血藤15~20份,赤芍10~15份,凌霄花5~15份,山药10~20份,枸杞5~10份,大枣10~15份;
所述外敷药物中,各种原料的重量份数比为:金黄散15~30份,透骨草10~20份,金银花10~20份,鸡血藤10~30份,地肤子10~20份,青黛10~15份,蛇床子10~20份,败酱草20~30份,地桃花10~20份,蒲公英10~20份,凌霄花15~20份。
5.根据权利要求1~4中任一项所述治疗妇女慢性盆腔炎的中药制剂,其特征在于,所述内服药物,在使用时煎汤剂服用,每日1剂,水煎分两次服,每7天为一疗程。
6.根据权利要求1~4中任一项所述治疗妇女慢性盆腔炎的中药制剂,其特征在于,所述内服药物剂型为片剂或散剂,服用时,一天三次,每7天为一疗程。
7.根据权利要求1~4中任一项所述治疗妇女慢性盆腔炎的中药制剂,所述内服药物的剂型:蜜炼丸剂、水合丸剂、胶囊、口服液、颗粒剂、胶剂或糖浆剂。
8.一种如权利要求1~4中任一项所述治疗妇女慢性盆腔炎的中药制剂的制备方法,其特征在于,所述内服药物散剂的制备包括:
粉碎的步骤:将所述原料按配比混合,投入粉碎机粉碎成细粉,粒度为80~120目;
混合的步骤:将上述步骤所得细粉投入混合搅拌机充分混匀;
包装的步骤:将混匀后的细粉用小瓶或包装盒分装,每3~5克为一瓶或一盒分装。
9.一种如权利要求1~4中任一项所述治疗妇女慢性盆腔炎的中药制剂的制备方法,其特征在于,所述外敷药物的制备包括以下步骤:
将所述原料加水浸泡30分钟至1小时,加热煮沸30~40分钟,过滤,滤液备用;滤渣加水第二次加热,煮沸30~40分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸40~50分钟,过滤;将三次滤液合在一起,加热浓缩至糊状,放入烘箱80℃烘干后冷却,研磨成细粉状;以每袋0.5~2g分装袋中,即成粉剂中成药。
10.根据权利要求9所述治疗妇女慢性盆腔炎的中药制剂的制备方法,其特征在于,所述外敷药物剂型为栓剂,制备的步骤包括:
取半合成脂肪酸甘油酯、羊毛脂、聚乙二醇和泊洛沙姆poloxamer中一种或多种作为基质;
将所述基质在温度50℃~60℃条件下加热融化,加入所述外敷药物的粉剂中成药,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,插入棉栓,冷却定型制成子弹头状栓剂;所述粉剂中成药与基质的配比为1∶2~1∶4;所述棉栓为尾部带有棉线的棉栓。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810238466XA CN101433654B (zh) | 2008-12-19 | 2008-12-19 | 一种治疗妇女慢性盆腔炎的中药制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810238466XA CN101433654B (zh) | 2008-12-19 | 2008-12-19 | 一种治疗妇女慢性盆腔炎的中药制剂及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101433654A CN101433654A (zh) | 2009-05-20 |
| CN101433654B true CN101433654B (zh) | 2010-12-29 |
Family
ID=40708394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810238466XA Expired - Fee Related CN101433654B (zh) | 2008-12-19 | 2008-12-19 | 一种治疗妇女慢性盆腔炎的中药制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101433654B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109276674A (zh) * | 2017-07-19 | 2019-01-29 | 邓泽潭 | 一种治疗盆腔炎的内服中药组合物 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283770B (zh) * | 2011-05-24 | 2012-10-31 | 河南中医学院 | 熏洗坐浴器 |
| CN104147482A (zh) * | 2014-07-24 | 2014-11-19 | 烟台瑞智生物医药科技有限公司 | 一种治疗气虚血瘀证型慢性盆腔炎的中药 |
| CN104306637A (zh) * | 2014-11-05 | 2015-01-28 | 青岛恒波仪器有限公司 | 一种治疗妇女脾虚湿盛型带下的中药组合物及其制备方法 |
| CN104435397A (zh) * | 2014-11-24 | 2015-03-25 | 周舜宁 | 一种治疗慢性盆腔炎的中药组合物 |
| CN104547149A (zh) * | 2014-12-14 | 2015-04-29 | 薛伟 | 一种治疗宫外孕术后慢性盆腔炎的中药外敷剂及护理方法 |
| CN104547964A (zh) * | 2015-02-13 | 2015-04-29 | 范江诺 | 一种治疗慢性盆腔炎的中药组合物及制剂 |
| CN104906465A (zh) * | 2015-06-25 | 2015-09-16 | 青岛大学附属医院 | 一种治疗妇女慢性盆腔炎的中药化瘀组合物及其制备方法 |
| CN105456945A (zh) * | 2016-01-02 | 2016-04-06 | 郑晓庆 | 一种治疗盆腔炎的中药制剂及制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1104906A (zh) * | 1994-05-25 | 1995-07-12 | 田庆涛 | “妇痛宁”保健袋 |
| CN1457831A (zh) * | 2003-04-18 | 2003-11-26 | 侯增光 | 经络血管动力药 |
-
2008
- 2008-12-19 CN CN200810238466XA patent/CN101433654B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1104906A (zh) * | 1994-05-25 | 1995-07-12 | 田庆涛 | “妇痛宁”保健袋 |
| CN1457831A (zh) * | 2003-04-18 | 2003-11-26 | 侯增光 | 经络血管动力药 |
Non-Patent Citations (3)
| Title |
|---|
| 张清龙等.活血化瘀治疗慢性盆腔炎192例观察.《实用医技》.2000,第7卷(第11期), * |
| 班秀文.养血通脉汤.《广西中医药》.1991,第14卷(第3期), * |
| 郭凤荷等.慢性盆腔炎的中医综合治疗.《中医药研究》.1996,(第1期), * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109276674A (zh) * | 2017-07-19 | 2019-01-29 | 邓泽潭 | 一种治疗盆腔炎的内服中药组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101433654A (zh) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048894B (zh) | 一种治疗烧伤的中药组合物及其制备方法 | |
| CN101804166B (zh) | 一种治疗小儿皮炎湿疹的中药组合物 | |
| CN101912593B (zh) | 一种用于治疗痛经的药物及其制备方法 | |
| CN101496862B (zh) | 一种治疗不孕的中药组合物及其制备方法 | |
| CN101433654A (zh) | 一种治疗妇女慢性盆腔炎的中药制剂及其制备方法 | |
| CN102178800B (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
| CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
| CN102178814B (zh) | 一种治疗滴虫性阴道炎的中药组合物及其制备方法 | |
| CN102058715B (zh) | 一种治疗慢性前列腺炎的中药制剂及其制备方法 | |
| CN102000164B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
| CN101433655B (zh) | 一种治疗阴道炎的中药组合物 | |
| CN102462827A (zh) | 治疗波尔山羊产后乳房炎中药散剂配方 | |
| CN101642548B (zh) | 治疗腰腿疼痛的中药膏贴及其制备方法 | |
| CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
| CN101637552B (zh) | 一种防治慢性盆腔炎的中药组合物 | |
| CN104784538B (zh) | 一种治疗糖尿病的中药制剂及制备方法 | |
| CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
| CN102895610A (zh) | 一种治疗水肿的药物 | |
| CN102526620B (zh) | 一种治疗妇科炎症的中药组合物及应用 | |
| CN101890081A (zh) | 一种治疗女性不孕不育的中药配方及其加工方法 | |
| CN101194968B (zh) | 一种治疗荨麻疹的中药制剂 | |
| CN103055115A (zh) | 一种治疗婴儿湿疹的中成药 | |
| CN101850101B (zh) | 一种治疗漏下的中药组合物及其制备方法 | |
| CN102755553A (zh) | 用于过敏性紫癜的紫银赤柏汤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101229 Termination date: 20111219 |